Roy Hartvig Larsen

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway.

Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway.

Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway.

Sciencons AS is an investment company that focuses on research and development businesses. The company was founded on January 2, 2014 and is headquartered in Oslo, Norway.

Sciencons Ltd. operated as a dormant company. The company was founded by Roy Hartvig Larsen on November 7, 2006 and was headquartered in London, the United Kingdom.

Part of Artbio, Inc., Artbio AS is a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines. The company is based in Oslo, Norway. The Norwegian company was founded in 2018. The CEO is Emanuele Ostuni.

Artbio, Inc. is a company that is focused on redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building an ecosystem that maximizes their potential. Artbio is based in Cambridge, MA and has subsidiaries in Norway. The company puts the patient at the core of everything they do. The company was founded in 2021 by Emanuele Ostuni, Roy Hartvig Larsen, and Øyvind Sverre Bruland. Emanuele Ostuni has been the CEO since 2021.